The radiotherapy quality assurance gap among phase III cancer clinical trials.
Quality assurance
Radiotherapy
Randomized controlled trials
Journal
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
ISSN: 1879-0887
Titre abrégé: Radiother Oncol
Pays: Ireland
ID NLM: 8407192
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
received:
15
07
2021
revised:
14
11
2021
accepted:
15
11
2021
pubmed:
29
11
2021
medline:
20
4
2022
entrez:
28
11
2021
Statut:
ppublish
Résumé
Quality assurance (QA) practices improve the quality level of oncology trials by ensuring that the protocol is followed and the results are valid and reproducible. This study investigated the utilization of QA among randomized controlled trials that involve radiotherapy (RT). We searched ClinicalTrials.gov in February 2020 for all phase III oncology randomized clinical trials (RCTs). These trials were screened for RT-specific RCTs that had published primary trial results. Information regarding QA in each trial was collected from the study publications and trial protocol if available. Two individuals independently performed trial screening and data collection. Pearson's Chi-square tests analyses were used to assess factors that were associated with QA inclusion in RT trials. Forty-two RCTs with RT as the primary intervention or as a mandatory component of the protocol were analyzed; the earliest was started in 1994 and one trial was still active though not recruiting. Twenty-nine (69%) trials mandated RT quality assurance (RTQA) practices as part of the trial protocol, with 19 (45%) trials requiring institutional credentialing. Twenty-one (50%) trials published protocol deviation outcomes. Clinical trials involving advanced radiation techniques (IMRT, VMAT, SRS, SBRT) did not include more RTQA than trials without these advanced techniques (73% vs. 65%, p = 0.55). Trials that reported protocol deviation outcomes were associated with mandating RTQA in their protocols as compared to trials that did not report these outcomes (100% vs. 38%, p < 0.001). There is a lack of RTQA utilization and transparency in RT clinical trials. It is imperative for RT trials to include increased QA for safe, consistent, and high-quality RT planning and delivery.
Identifiants
pubmed: 34838891
pii: S0167-8140(21)09010-1
doi: 10.1016/j.radonc.2021.11.018
pmc: PMC8900671
mid: NIHMS1759668
pii:
doi:
Types de publication
Journal Article
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
51-57Subventions
Organisme : NCI NIH HHS
ID : P30 CA016672
Pays : United States
Informations de copyright
Copyright © 2021 Elsevier B.V. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of Interest Dr. Prajnan Das: Honorarium: ASCO, ASTRO, NCI/Leidos, Physicians Education Resource, Conveners (all unrelated to this manuscript’s content). No other authors report any conflicts of interest.
Références
Radiat Oncol. 2018 Jun 7;13(1):108
pubmed: 29880015
Int J Radiat Oncol Biol Phys. 2012 Feb 1;82(2):809-16
pubmed: 21277694
Int J Radiat Oncol Biol Phys. 2009 Feb 1;73(2):492-8
pubmed: 18804334
J Appl Clin Med Phys. 2018 Sep;19(5):335-346
pubmed: 29959816
Int J Radiat Oncol Biol Phys. 1984 Jun;10 Suppl 1:119-25
pubmed: 6735787
Pract Radiat Oncol. 2013 Jul-Sep;3(3):157-163
pubmed: 24674359
Med Phys. 2016 Dec;43(12):6491
pubmed: 27908168
Int J Radiat Oncol Biol Phys. 2019 Oct 1;105(2):329-337
pubmed: 31299242
Radiother Oncol. 2015 Mar;114(3):285-8
pubmed: 25727681
Radiother Oncol. 2014 Jun;111(3):327-9
pubmed: 24813094
Int J Radiat Oncol Biol Phys. 2008;71(1 Suppl):S71-5
pubmed: 18406942
J Med Imaging Radiat Oncol. 2013 Apr;57(2):247-57
pubmed: 23551788
Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):315-6
pubmed: 20394859
J Clin Oncol. 2010 Jun 20;28(18):2996-3001
pubmed: 20479390
Radiother Oncol. 2019 Aug;137:1-8
pubmed: 31039468
Int J Radiat Oncol Biol Phys. 2017 Aug 1;98(5):1197-1203
pubmed: 28721904
Eur J Cancer. 2017 Nov;86:91-100
pubmed: 28964907
Int J Radiat Oncol Biol Phys. 2013 Mar 15;85(4):904-11
pubmed: 23040217
Int J Radiat Oncol Biol Phys. 2014 Dec 1;90(5):1242-9
pubmed: 25539374
Pract Radiat Oncol. 2020 Sep - Oct;10(5):372-381
pubmed: 32413413
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):782-90
pubmed: 22425219
Int J Radiat Oncol Biol Phys. 2012 Jul 1;83(3):773-81
pubmed: 22445001
Eur J Cancer. 2012 Nov;48(17):3232-9
pubmed: 22766515
Radiother Oncol. 2012 Oct;105(1):4-8
pubmed: 22985777
Int J Radiat Oncol Biol Phys. 2020 Feb 1;106(2):243-252
pubmed: 31288053
J Natl Cancer Inst. 2013 Mar 20;105(6):387-93
pubmed: 23468460
Int J Radiat Oncol Biol Phys. 2018 Jul 15;101(4):927-934
pubmed: 29976505
Semin Radiat Oncol. 1997 Apr;7(2):97-100
pubmed: 10717202
J Natl Cancer Inst. 2013 Mar 20;105(6):376-7
pubmed: 23468459
Int J Radiat Oncol Biol Phys. 2021 Jul 15;110(4):993-1002
pubmed: 33561507
Front Oncol. 2019 Aug 21;9:792
pubmed: 31497534
Semin Radiat Oncol. 2008 Jul;18(3):201-6
pubmed: 18513630
Radiother Oncol. 2008 Feb;86(2):195-9
pubmed: 17727987
Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1333-8
pubmed: 19540060
J Res Natl Inst Stand Technol. 2013 Dec 30;118:403-18
pubmed: 26401441
Radiother Oncol. 2012 Oct;105(1):9-13
pubmed: 23084596
Int J Radiat Oncol Biol Phys. 2018 Dec 1;102(5):1590-1591
pubmed: 30063942
JAMA. 1988 Sep 23-30;260(12):1743-8
pubmed: 3045356
Milbank Mem Fund Q. 1966 Jul;44(3):Suppl:166-206
pubmed: 5338568
J Med Phys. 2013 Jul;38(3):111-4
pubmed: 24049316